Skip to main content
Premium Trial:

Request an Annual Quote

Thomas Widmann

Thomas Widmann has been appointed to the board of Cancer Genetics. He founded Actelion Pharmaceuticals and is a venture partner at Wellington Partners. Wildmann is also the founder of Hesperion, Widmann Associates, and Auraglobe. Before that he spent nine years at Hoffmann-La Roche where he led the international cardiovascular development department. 

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.